Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Insulin infusion protocol Clear all
Completed Not applicable Interventional

Comparison of Intraoperative Best Practice Advisory Reminders to Protocolize Insulin Administration Versus Standard Care in Patients at High Risk of Hyperglycemia

NCT05426096
View directory record Official record
Conditions
Diabetes, Hyperglycemia
Interventions
Best Practice Advisory
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
7,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 5, 2026, 9:03 AM EDT
Withdrawn Phase 1 Interventional

Dexamethasone/Pancreatic Clamp P&F

NCT06126354
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 5, 2026, 9:03 AM EDT
Withdrawn Phase 3 Interventional

Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia

NCT00943709
View directory record Official record
Conditions
Hyperglycemia, Leukemia
Interventions
insulin glargine recombinant, therapeutic insulin
Biological · Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Sep 5, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

Pancreatic Clamp in NAFLD

NCT05724134
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, CORE Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 5, 2026, 9:03 AM EDT
Active, not recruiting Phase 2 Interventional

Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes

NCT04542148
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk, Diabetes, Gestational
Interventions
Sliding Scale Insulin, Up-Titration of Home Insulin, Continuous Insulin Infusion, Dexcom G6 Professional Continuous Glucose Monitor
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 50 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Portland, Oregon • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 5, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU

NCT00394524
View directory record Official record
Conditions
Diabetes or With New Hyperglycemia
Interventions
Glucommander, Standard insulin infusion algorithm
Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Atlanta, Georgia • Memphis, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 5, 2026, 9:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids

NCT03912363
View directory record Official record
Conditions
Type II Diabetes Mellitus, Gestational Diabetes Mellitus
Interventions
Rotating fluids protocol, Insulin infusion protocol
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
14 Years to 50 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 5, 2026, 9:03 AM EDT
Not yet recruiting Phase 1 Interventional

Human Models of Selective Insulin Resistance: Pancreatic Clamp

NCT06558422
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Diagnostic Test · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 5, 2026, 9:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strict or Liberal Insulin Protocol Following Coronary Artery Bypass Graft (CABG) Surgery

NCT01033916
View directory record Official record
Conditions
Blood Glucose, Coronary Artery Bypass, Insulin, Coronary Disease
Interventions
LIBERAL
Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Sep 5, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose

NCT01187329
View directory record Official record
Conditions
Hyperglycemia, Aortic Valve Replacement, Aortic Stenosis, Cardiac Surgery
Interventions
hyperinsulinemic normoglycemic clamp (HNC), control group
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 84 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Sep 5, 2026, 9:03 AM EDT
Enrolling by invitation Phase 1 Interventional

Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy

NCT05973734
View directory record Official record
Conditions
Islet Transplantation
Interventions
Infusion of recipient T regulatory cell, Infusion of concomitant Donor Derived Vertebral Bone Marrow
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 5, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Intensive Insulin Therapy in Deceased Donors

NCT01140035
View directory record Official record
Conditions
Kidney Transplant
Interventions
Administration of continuous insulin infusion for glycemic control in brain dead donors
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Sep 5, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus

NCT02772783
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
high GI meal, low GI meal, euglycemic insulin clamp, primed-variable insulin infusion
Other · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 5, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

NCT00813605
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
FOLFIRI, AMG 655, Placebo, AMG 479
Other · Biological
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
28
States / cities
Beverly Hills, California • Los Angeles, California • Santa Maria, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 5, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial

NCT03195140
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Predictive Low Glucose Suspend
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
6 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Palo Alto, California • Santa Barbara, California • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Sep 5, 2026, 9:03 AM EDT
Terminated Not applicable Interventional

Pramlintide Combined With Model Predictive Control Algorithm

NCT01434862
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Closed loop with pramlintide, Closed loop without pramlintide, Open loop with pramlintide
Drug · Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 5, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional Results available

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

NCT00642941
View directory record Official record
Conditions
Sarcoma
Interventions
RG1507
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
22
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 5, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Results available

Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus

NCT04599075
View directory record Official record
Conditions
Type 1 Diabetes, Pregnancy, High Risk
Interventions
Insulin
Drug
Lead sponsor
Gianna Wilkie
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2024 · Synced Sep 5, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

IV Insulin Protocol in Diabetes and Renal Transplantation

NCT00609986
View directory record Official record
Conditions
Kidney Transplantation, Diabetes, Hyperglycemia
Interventions
insulin, NPH Insulin or glargine insulin and aspartame insulin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Sep 5, 2026, 9:03 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

NCT00670228
View directory record Official record
Conditions
AMI
Interventions
Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Sep 5, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

The Effect of Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery

NCT01831154
View directory record Official record
Conditions
Diabetes, Hyperglycemia, Surgical Site Infection
Interventions
Tight Glycemic, Conventional Glycemic, Standard Glycemic
Drug
Lead sponsor
James A. Haley Veterans Administration Hospital
Federal
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Sep 5, 2026, 9:03 AM EDT
Withdrawn Phase 2 Interventional

MAGIK for Femoral/Tibial Shaft Fractures

NCT05627479
View directory record Official record
Conditions
Femoral Shaft Fracture, Tibial Shaft Fracture
Interventions
GIK solution, Isotonic Normal Saline Solution
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 5, 2026, 9:03 AM EDT
Completed Phase 4 Interventional

Comparison of the Leuven Protocol With the Glucommander for Postoperative Control of Blood Glucose With IV Insulin

NCT00795015
View directory record Official record
Conditions
Diabetes
Interventions
insulin regular IV infusion, IV insulin infusion
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Sep 5, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set

NCT02687256
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Extended Wear infusion set, Standard Infusion set, Heparin
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 5, 2026, 9:03 AM EDT